Clinical Trials
13 trialsNCT05496959 2026-05-26
LUNAR
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05616650 2026-05-22
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05830838 2026-05-20
DAPPER
Mayo Clinic
Phase NA Active not recruiting
NCT04423211 2026-05-15
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT03644303 2026-05-14
TRAP
Royal Marsden NHS Foundation Trust
Phase NA Completed
NCT05169970 2026-05-13
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06523634 2026-05-12
STEREOBED
Jules Bordet Institute
Phase NA Recruiting
NCT04262154 2026-05-11
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04644770 2026-05-08
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT07548164 2026-05-08
Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 3 Recruiting
NCT02206334 2026-05-07
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer
NRG Oncology
Phase 1 Completed
NCT05946213 2026-05-07
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NRG Oncology
Phase 3 Recruiting
NCT05053152 2026-05-04
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
NRG Oncology
Phase 2 Active not recruiting